About Adjuvatis
Founded in December 2013, Adjuvatis is specialized in the development, manufacturing and formulation of two innovative delivery systems, called i-Particles® and i-LipoP®.
i-Particles® were initially developed in 2003 by a joint research unit between the French National Center for Scientific Research (CNRS) and bioMérieux company, a global leader in in vitro diagnostics. Ten years of development raised promising interests in many healthcare fields and led to the creation of Adjuvatis. More recently, i-LipoP®, has emerged from the 2020 public health crisis, allowing vectorization of nucleic acids.
From R&D to production, Adjuvatis offers a wide variety of i-Particles® and i-LipoP®-based products and operates services for API formulation in the fields of vaccines, drug delivery and diagnostics. Adjuvatis also provides analytical services for customers’ formulations and colloidal technologies.
Providing high quality formulations for pharmaceutical and diagnostic industries
Built around a safe-by-design concept and biosafety concerns, Adjuvatis is committed in promoting innovative and safe solutions to improve customer’s formulations. i-Particles® and i-LipoP® provide improvements about healthcare, cost-effectiveness and quality aspects related to three main fields.
VACCINES
Increase immunogenicity, insure biosafety
i-Particles® and i-LipoP® stands as a new class of adjuvant by supporting the development of more efficient and safer vaccines.
DRUG DELIVERY
Develop safe-by-design formulation, potentiate efficacy
Our technologies insure solubilization, protection, targeted and sustained delivery of your API, leading to a better efficacy and limited toxicity.
DIAGNOSTICS
Improve cost-effectiveness, highlight eco-compatibility
Functionnalized plain and dyed i-Particles®, based on antigen-antibody recognition, open the way of biodegradable and low-cost diagnostic tools.
Adjuvatis benefits from a unique environment
At the heart of the Bioparc Lyon (France) which gathers companies and start-up specialized in the health sector, universities of medicine and pharmacy, research centers and hospitals.
A broad spectrum of expertise dedicated to your formulation
Supported by a referent advisory board and external experts, Adjuvatis team gathers expertise in chemistry, biology, pharmaceutical sciences, manufacturing and partnering. Working collaboratively, we are committed to innovation for your therapeutic product development. To insure partners and customers satisfaction, Adjuvatis implements a quality-dedicated way of working integrating both skills and experience. Adjuvatis provides cutting-edge services for formulation development of customers’ biopharmaceuticals.
Bernard VERRIER
Bernard MANDRAND
David DA COSTA
Our privileged partners
From extending our technological network to supporting innovation, our scientific partners widen our panel of expertise and contribute with us to strive for excellence. To explore licensing opportunities, collaborative researches, or commercial partnerships, feel free to contact us.
European and national innovative programs
European Innovative Training Network DRIVE (funding H2020) 2017-2021 - Driving next generation autophagy researchers towards translation
Partners
15 beneficiaries
20-partners organisation
National project, ASIO (funding ANR) 2014-2018 - Advanced Skin Immunity by omics analysis
Partners
CEA/list DM2I/LADIS
IMABIOTECH ImaBiotech SAS
INSERM 1135 Cimi-Paris Institut National de la Santé et de la Recherche Medicale
PRISM Laboratoire de Spectrométrie de Masse Biologique, Fondamentale et Appliquée, Université Lille1
European project, FluNanoAir (funding EuroNanoMed 3) 2016-2019 - Design of Human Influenza vaccines using multifunctional micelles harnessing innate immunity
Partners
Plana Prades, Fundació Clínic per la Recerca Biomèdica (FCRB), Spain
Cox Rebecca, University of Bergen, Norway
Le Grand Roger, Commissariat à l’Energie Atomique (CEA), France
National project, PaNaCée (funding ANR and DGA, French army) 2014-2017 - Biodegradable and bioactive nanostructures for functional reconstruction of cutaneous wound
Partners
INSERM 1135 Cimi-Paris Institut National de la Santé et de la Recherche Medicale
IRBA Institut de recherche biomédicale des armées
LBTI – CNRS Laboratoire de Biologie Tissulaire et Ingénierie Thérapeutique